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EDITORIAL
Prostate cancer is the most common cancer in men in the 
UK, accounting for nearly a quarter of all new male cancer 
diagnoses and around 12% of all male cancer deaths.1 Based 
on a similar time period, incidence rates in the USA are even 
higher at 56.9 per 100 000 men for all races and 234.6 per 
100 000 for black men. One in 6 American men are at risk of being 
diagnosed with cancer of the prostate during their lifetime.2
An increased risk of cancer of the prostate is related primarily to 
age and family history and to a lesser extent to race. Prevalence is 
low under the age of 50 years and peaks at 50 - 80 years, while 5 - 
10% of cases are thought to have a substantial inherited component, 
black men having an approximately trebled risk.2 Prevalence rates 
have increased in recent times, partly due to increased case finding 
in asymptomatic men who are screened, and in tissue removed at 
transurethral prostatectomy for benign prostatic hypertrophy, where 
prostate cancer has been reported in up to 10% of cases.3
Cancer of the prostate is largely a disease of older men, and many 
cancers detected in asymptomatic patients will be indolent and slow-
growing and will not shorten life. The average age of death from this 
disease in the UK is 80 - 84 years; by the age of 80 years, approximately 
80% of men will have some cancer cells in their prostate. Many of 
these men will die from unrelated causes. Therefore, although 1 in 26 
men (3.8%) in England and Wales will die from prostate cancer, many 
more will have low-risk indolent tumours and will die with, rather 
than from, the disease. By comparison, 1 in 2 men will die from 
cardiovascular disease and 1 in 53 from colon cancer.4
Cancer of the prostate is not a single disease entity, and its natural 
history is still not fully understood. It is rather a spectrum of 
diseases, ranging from indolent slow-growing tumours that may not 
cause any symptoms or shorten life, to aggressive rapidly growing 
tumours. However, some tumours change from being low-risk and 
slow-growing to high-risk aggressive tumours, and it is not possible 
to accurately predict which tumours will behave in such a manner.4 
Therein lies the dilemma posed by screening programmes, which 
usually target older men (over the age of 50 years). Apart from 
uncertainties around the effectiveness of screening and a reported 
incidence of false-positive results of 10 - 15%5 – with the associated 
anxiety that this creates6 – many men will be at risk of undergoing 
aggressive surgical and irradiation therapy for a disease they may 
die with, rather than from. More recent access to less invasive 
brachytherapy may partially reduce this risk, but at what cost? It 
is almost inevitable that this less invasive treatment will also be 
over-used because of the same uncertainties that have influenced 
treatment choices until now, and the cost will undoubtedly limit 
access in the current funding environment.
It has recently been shown that with the type of cancer detected 
by screening an ageing population, 1 410 men will need to be 
screened and 48 treated for prostatic cancer to save one life, and 
a significant number of those may be left incontinent or impotent 
as a consequence.5 Does the benefit of screening for prostate 
cancer in an older population outweigh the risk? Overdiagnosis and 
overtreatment of prostatic malignancy, because of the absence of a 
good way of detecting which cancers will progress, arguably poses 
one of the major challenges of current clinical practice. Although the 
American health care model has advocated screening with digital 
rectal examination and prostatic specific antigen (PSA) since the 
early 1990s, there are still no specific guidelines in place in the UK, 
either for screening of high-risk families or of the general population, 
because of the above uncertainties.
Much hope was pinned on the completion of two recent landmark 
trials that studied the effect on mortality of screening for prostate 
cancer, viz. the European Randomized Study of Screening for Prostate 
Cancer (ERSPC) and the US-based Prostate, Lung, Colorectal, and 
Ovarian (PLCO) Cancer Screening Trial.6,7 Both were extraordinary 
trials with an unprecedented magnitude of enrolled subjects, but 
failed to answer the critical questions. Both trials showed that 
the majority of cancers diagnosed were at stage 2, were nearly all 
adenocarcinomas, but there was little or no effect on mortality from 
the disease over a prolonged follow-up period. However, data from 
both trials support the notion that the benefits from screening may 
be restricted to younger age groups and that screening may be more 
important in these individuals.
Against this background, Heyns and colleagues report in this issue 
of the SAMJ their study on prostate cancer in younger men (under 
the age of 50 years). This is a retrospective review from an academic 
tertiary hospital, of a large number of patients without previous 
access to screening, who presented with prostate cancer, most being 
symptomatic at presentation. Notwithstanding the racial bias of this 
sample, which might have included relatively more high-risk patients 
than other reported studies, their data show quite convincingly that 
this age group included a significantly greater proportion of advanced 
high-grade tumours, with shorter survival than in older age groups. 
This finding lends some support to the notion espoused by the 
authors of the two recent international studies, that any mortality 
benefits to be achieved from screening are more likely to be achieved 
in younger patients, who would appear from this particular study 
to harbour higher-risk carcinomas that may benefit from earlier 
intervention. In reporting their experience, the authors have made a 
significant contribution to further understanding this disease in the 
South African context, and are to be commended.
Only 3% of the 1 571 patients reported by Heyns et al. were under 
the age of 50, and the low prevalence of prostatic carcinoma in this 
age group has implications when contemplating extending the age at 
which to commence screening. Restricting screening to individuals 
with risk factors such as positive family history in first-degree 
relatives may be a consideration. From an individual perspective, in 
a private health care setting, where individuals are fully informed of 
risks and benefits and funders willing to shoulder the increased cost 
burden, this policy could be considered. However, from the broader 
population perspective, and in the light of current uncertainties 
around the natural history of this disease, screening for prostatic 
carcinoma in any age group is unlikely to prove cost beneficial.
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